Roche

Roche

unknown New Zealand

Roche is a prominent figure in New Zealand's public sector, serving in a role that involves oversight of various government agencies. Following a recent inquiry into data management failures related to the Manurewa Marae, Roche described the findings as a 'massive wake-up call' and emphasized the need for reforms to restore public trust in the handling of sensitive information.

Global Media Ratings
Dominance
0.00%
Persistence
1 wks
Reach
26,445
Power
2,139$
Sentiment
6.67
Countries Mentioned
Country Mentions Sentiment Dominance + Persistence x Population = Reach x GDP (millions) = Power
Switzerland 3 6.67 0.28% +10% 8,654,622 26,445 $700,000 2,139$
Totals 3 8,654,622 26,445 $700,000 2,139$
Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

Switzerland Switzerland: Roche is a pharmaceutical company that is crucial for the Swiss economy and should avoid being affected by Trump's tariffs. 7

Neue Zürcher Zeitung: Die Schweiz exportiert mehr denn je in die USA

Switzerland Switzerland: Roche is one of the largest pharmaceutical companies that is investing in new production capacities in the USA. 7

Neue Zürcher Zeitung: Trump und die Schweiz: Den Handelsbilanzüberschuss interaktiv senken

Switzerland Switzerland: Roche is one of the Swiss pharmaceutical companies that may soon agree to terms with the White House. 5

Neue Zürcher Zeitung: Trump schliesst Deals mit Pharmafirmen

Switzerland Switzerland: Roche has announced investments of 50 billion dollars in the USA for new production capacities. 7

Neue Zürcher Zeitung: Kann die Schweiz das Handelsbilanzdefizit eliminieren?

Switzerland Switzerland: Swiss pharmaceutical giant Roche has promised to largely shift production for the American market to the USA. 5

Neue Zürcher Zeitung: BIP schrumpft wegen Trumps Zöllen im dritten Quartal

Switzerland Switzerland: Roche is considered significantly undervalued and has strong prospects in its diagnostics division. 8

Neue Zürcher Zeitung: «In der Summe ist Roche deutlich unterbewertet»